Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/6/2026 | $7.00 → $9.00 | Buy | H.C. Wainwright |
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition. Dr. Gupta is an experienced CEO who brings more than two decades of transformative leadership across biopharmaceuticals, global he
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas (GEA)
ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company's senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026. Conference details are as follows: 2026 Jefferies Global Healthcare ConferenceFormat: Company Presentation and one-on-one investor meetingsDate: Thursday, June 4, 2026Presentation time: 3:10 PM ET Webcast Link: Here The webcast of the Jefferies presentation will be accessible on th
4 - NovaBridge Biosciences (0001778016) (Issuer)
4 - NovaBridge Biosciences (0001778016) (Issuer)
4 - NovaBridge Biosciences (0001778016) (Issuer)
4 - NovaBridge Biosciences (0001778016) (Issuer)
6-K - NovaBridge Biosciences (0001778016) (Filer)
6-K - NovaBridge Biosciences (0001778016) (Filer)
20-F/A - NovaBridge Biosciences (0001778016) (Filer)
H.C. Wainwright resumed coverage of NovaBridge Biosciences with a rating of Buy and set a new price target of $9.00 from $7.00 previously
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition. Dr. Gupta is an experienced CEO who brings more than two decades of transformative leadership across biopharmaceuticals, global he
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussionsStrong industry reputation and commercial track record in high-value pharmaceutical markets including oncology and ophthalmologyStrengthens NovaBridge's leadership team as the Company advances givastomig, a potential first-in-class Claudin 18.2 x 4-1BB bispecific antibody for first line (1L) gastric cancer, toward registrational pivotal studies and continues to advance VIS-101, purpose-designed, potential best-in-class, dual VEGF-A x ANG-2 inhibitor for wet AMD ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- NovaBridge Bioscienc
Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA's Accelerated Approval Pathway with potential initiation of a registrational Phase 3 trial as early as Q4 2026VIS-101, a potential best-in-class VEGF-A X ANG-2 inhibitor for wet-AMD, produced rapid, robust and durable responses in treatment naïve wet-AMD patients, and is poi
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMDVIS-101 demonstrated mean BVCA improvements of >10 ETDRS letters and median CST reductions of 100-150 mmPotentially best-in-class durability with a favorable safety profile and no dose-limiting toxicityPhase 2b dose-determining study expected to begin in H2 2026; global Phase 3 program expected to begin in 2027Conference Call and Webcast today, March 09 at 9:00 AM ET ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or t